Related Interviews

The First Half of 2019 Expected to Be Rough for the Biotech Sector
March 15, 2019
Singh, Hartaj

Biotech Space Lining Up for New Product Cycle
April 21, 2017
Singh, Hartaj

Integrating a Top-Down View with a Bottom-Up Investment Approach
March 24, 2017
Snell, Patrick

Investing in Disruptive High-Growth Companies
April 08, 2016
Tubbs, Leslie

Looking for the World’s Best Companies with the Best Balance Sheets
November 06, 2015
Edgerton, Bobby

Strong Fundamentals in Biotech Justify Even Higher Valuation Levels
December 11, 2014

Biotech Space Concentrates on Gene Therapy, CAR T-Cell Technology Side
July 23, 2014

A Large-Cap Growth Strategy Focused on Capital Appreciation and Income
January 28, 2014

Increased Biotech Productivity and Innovation Reflected in FDA-Approved Drugs
August 23, 2013

High Success Rates and Significant M&A in the Antibody Space
April 16, 2013

U.S. Biotech Valuations Appear Attractive Despite Earlier Run
August 17, 2012

Nano Manufacturing Prospects In Semiconductors - Daniel Heyler - Bank Of America Merrill Lynch (asia Pacific) Ltd.
June 13, 2011

Health Care Services & Tech Outlook - Ross Muken - Deutsche Bank Securities, Inc.
November 15, 2010

INVESTING IN DIABETES-RELATED STOCKS - DAVID A. KLIFF - DIABETIC INVESTOR
November 17, 2008

Roundtable Forum: Gaming
October 06, 2003

L.holtz / Y.lipsker - Roger Engemann & Associates
July 28, 2003

Ian Smith - Vertex Pharmaceuticals Inc (vrtx)
June 02, 2002

R.schwarzkopf / S.gleason - Kayne Anderson Rudnick Investment Mgmt Llc
February 25, 2002

R.crit Thomas - Armada Funds
February 04, 2002

Medical Device Companies / Small & Mid-cap: Charles Olsziewski - Ubs Warburg
October 12, 2001

Mark Frevert - Enron Wholesale Services (ene)
May 31, 2001

Harry Penner Jr. - Neurogen Corporation (nrgn)
December 02, 1999